News Releases

Month Year

Investor Alerts

Aug 7, 2017

Anika Announces Publication of Data Demonstrating the Efficacy and Safety of HYALOFAST® in Combination with Stem Cells for the Treatment of Cartilage Lesions on the Knee

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid...
Jul 26, 2017

Anika Announces Appointment of Joseph Darling as President

Track Record of Successful Product Launch and Global Commercial Expansion

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA"
Jul 24, 2017

Anika Announces Regulatory Approval for MONOVISC® in India for the Treatment of Pain Associated with Osteoarthritis of All Synovial Joints

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid...
Jul 17, 2017

Anika Announces $5 Million Milestone Payment from U.S. Commercial Sales of MONOVISC

Company Expects Total Revenue Growth of 23% to 26% for Q2 2017

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid...
Jul 12, 2017

Anika to Issue Second-Quarter 2017 Financial Results and Business Highlights on Wednesday, July 26

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its second-quarter 2017 financial results after the close of the market on...
Jul 6, 2017

Anika to Present at the Singular Research Summer Solstice Conference on July 13, 2017

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid...
May 30, 2017

Anika Announces Data Presentation and Symposium on CINGAL at 2017 EFORT Annual Congress

BEDFORD, Mass. & VIENNA--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary...
May 25, 2017

Anika Announces First Patient Enrolled in Supplemental Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid...
May 23, 2017

Anika Celebrates 25th Anniversary and Inaugurates Newly Expanded and Consolidated Global Manufacturing Facility in Bedford, Massachusetts

Ribbon-Cutting Ceremony Opens the Doors to State-of-the-Art Facility Built to Supply Global Demand for Anika's Extensive Commercial Portfolio of More than 20 Products and Technologies

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid...
May 22, 2017

Anika Announces Publication of Phase III Data Demonstrating the Efficacy and Safety of CINGAL® for the Treatment of Knee Pain Associated with Osteoarthritis

Positive Data Provides Further Rationale for Strong and Growing Physician Demand for CINGAL following Commercial Launches in Europe and Canada

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid...

Show per page